Heat therapy for cancer
This article was originally published in The Gray Sheet
Executive Summary
High-risk soft tissue sarcoma patients treated with BSD Medical's BSD-2000 hyperthermia system in addition to chemotherapy had nearly double the median time of disease free-survival (31.7 months) and local progression-free survival (45.3 months) compared with those only receiving chemotherapy, according to study results presented June 4 at the American Society of Clinical Oncology conference in Chicago. The 340-patient randomized trial was based on the belief that precision-focused, mild heating of cancer improves blood flow and leads to better absorption of chemotherapy drugs, in addition to directly killing cancer cells and improving chemical reactions of some drugs. BSD Medical submitted a PMA application for the BSD-2000 in May 2006 (1"The Gray Sheet" May 29, 2006, In Brief)...
You may also be interested in...
BSD-2000 PMA
BSD Medical submits premarket approval application for tumor hyperthermia therapy May 22. The PMA is based on data from approximately 4,000 treatments of more than 800 patients (1"The Gray Sheet" Jan. 19, 2006, p. 15). The device employs an array of radiofrequency antennae to generate enough energy to target and kill cancer cells...
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.